An interesting critique of the widely-circulated phase 3 trial reporting an unexpected improvement in overall survival with the use of protons versus photons for oropharyngeal cancer observes “22 patients [10%] in the proton group whose insurance was denied were immediately lost to follow-up and presumably censored at t=0,” noting insurance-type is a long-recognized correlate with overall survival. | McBride, Lancet 2026
